Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin and the lung

K J O'Byrne1, D N Carney

  • 1Department of Oncology, Mater Misericordiae Hospital, Dublin, Ireland.

Lung Cancer (Amsterdam, Netherlands)
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Novel therapies targeting lung cancer are needed. Somatostatin analogues show promise in inhibiting small cell lung cancer (SCLC) growth, paving the way for future clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.

Oncogenesis·2026
Same author

Rearranged during transfection (RET) lung cancer - Update on targeted therapies.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.

ESMO open·2023
Same author

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.

ESMO open·2022
Same author

Osteosarcoma and second malignant neoplasms: a case series.

Irish journal of medical science·2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung carcinoma is a leading cause of cancer death, with limited therapeutic advancements.
  • Small cell lung cancer (SCLC) expresses somatostatin, a finding requiring further investigation.
  • Novel therapeutic strategies are essential for treating lung tumors.

Purpose of the Study:

  • To evaluate the potential of somatostatin and its analogues in treating lung cancer.
  • To investigate the expression and functional significance of somatostatin receptors in SCLC.
  • To explore the therapeutic efficacy of somatostatin analogues in preclinical models.

Main Methods:

  • Assessing somatostatin receptor expression on SCLC cell lines and tumor samples.
  • Utilizing radiolabeled somatostatin analogues for scintigraphic imaging of SCLC.

Related Experiment Videos

  • Conducting in vitro proliferation assays with somatostatin analogues.
  • Performing in vivo xenograft studies with SCLC and non-small cell lung cancer models.

    • Main Results:

    • Somatostatin receptors are present on 50-75% of studied SCLC cell lines and samples.
    • Somatostatin analogues inhibited SCLC cell line proliferation in vitro.
    • In vivo studies demonstrated growth inhibition of SCLC xenografts by somatostatin analogues.
    • Evidence suggests somatostatin analogues may inhibit tumor growth through both direct and indirect mechanisms.

    Conclusions:

    • Somatostatin analogues represent a promising therapeutic avenue for lung cancer, particularly SCLC.
    • Targeting somatostatin receptors could offer a novel approach for SCLC detection, localization, and treatment.
    • Preclinical findings support the advancement of somatostatin analogue-based therapies into clinical trials.